Catalog No.: PC-73263Not For Human Use, Lab Use Only.
CCR4-IN-22 (Compound 22) is a potent, selective CCR4 antagonist with IC50 of 20 nM, efficiently inhibits CCR4-mediated Ca2+ mobilization and chemotaxis in vitro with IC50 of 3 and 7 nM, repectively.
CCR4-IN-22 (Compound 22) is a potent, selective CCR4 antagonist with IC50 of 20 nM, efficiently inhibits CCR4-mediated Ca2+ mobilization and chemotaxis in vitro with IC50 of 3 and 7 nM, repectively.
Compound 22 displays >500-fold less effective against other chemokine receptors (CCR2, CCR3 and CXCR3). and GPCRs (5-HT1A, 5-HT6 and 5-HT7).
Compound 22 suppressed eosinophil accumulation in the lungs of antigenimmunized mice in vivo, efficacious in a murine allergic inflammation model (ED50 10 mg/kg).
Compound 22, as well as anti-CCL17 or anti-CCL22 antibody selectively suppressed accumulation of Th2 cells and eosinophils in the lungs of Th2-transferred and OVA-challenged mice.
Compound 22 also inhibited bronchial hyperresponsiveness but had little effect on goblet cell hyperplasia in Th2-transferred and OVA-challenged mice.
